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JACC February I¢)g,~ ABSTRACTf~, P(~ler 1(tgA 
of agents, and developed and tested a reaction-diffusien model for myocar. 
dial penetration from the pericardial space. TM I.LysyHysine (LL), MW 420 D; 
~3~ I-NONO-AIb, MW 73 kD; and ~"~Tc.macreaggregated albumin (MAA), 30 
t~m diameter were delivered into the porcine pericardial space (n = 10) by a 
transmyocardiel route using a helix-needle (;atheter. Washout was assessed 
over "/2 h by serial Sctntigrsphy to dofine agent loss from the region of inter. 
est. Eptcardist-endocardtal concentration gradients (n = 5) established ;t h 
after agent delivery were assessed by measuring count rates of myocardial 
tissue series obtained by cryosectioning tangential to the eplcardiat sumacs, 
A maltmmatical model was tk~voloped based on a maction-diflusion ~luation 
~s~rlblng agent transfer into myocaKlium as a function of interstitial dlflu. 
sign, transcapi!ta, rywashout, penetration depth, and time, RHL was 98 ± 26 
h for MAA, 22 ~ 4 h for NONO-AIb, and 4,6 ± 0,5 h tor LL Sharp transmural 
concentration gradients were found for LL, with a penetration half.depth of 
~,5 ~t" 0.1 ram; these profiles were closely fit by our mathematical model [r 
0,95). In conclusion, physica! size el agents strongly influences intrapencar, 
dial residen(:e time; and transmural concentration gradients am steep, and 
well.modeled in terms of diftu~ion ~nd washout. These pharmacokinetic an~ 
tissue penetration ch~racteristtco will help to define appropriate agents and 
sutt~bl~ targets for intrapencardiat therapy. 
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~ Long-term Survival In Patients With Primary 
Syslemi¢ Amyloidosls Wlth Biopsy-proven 
Cardiac Involvement 
M. Grogan, MA. Gertz, RA. Kyle, J.B Seward. A.J. Taiik. Mayo Medical 
Center, Rochester, MN, USA 
Background: Prognosis in primary systemic areyloidosis with cardiac involve- 
ment is poor with a reported median survwal ot 5 months. The purpose of 
this study was to determine the frequency ot long-term survival (~5 yrS) ~n 
patients (pts) with pnmary systemic amyfoidesis with biopsy proven cardiac 
involvement. 
Methods: A review of all patients w;th i~nmary systemic amylo~des=s w=th 
biopsy proven cardiac involvement was performed. 
Results: One-hundred and fifty-tour pts with primary systemic amyloidosis 
with a positive cardiac (153 endomyocardial. I pencardial) biopsy for amyloid 
infiltration were seen from 1965 to 1997. Ten pts (~,o) were found to have 
long-term survival, with a median o! 138 months (range 76-181 ). Seven pts 
su~ved ~ 10 yrs and 6 of the 10 pts were alive at last follow up. All pts with 
long-term survival received chemotherapy, Median sunnval ot the remam=ng 
144 pts was 6 months. Initial EF was significantly higher (55 x 12 vs 47 
14%, p = . 0.001) and mean mitral deceleration time was longer (196 
7t vs 166 ± 45 msec, p =.  0.001) in pts wi|h ~5 yr survival. Initial septal 
thickness was not significantly different in those with - or -5 yr sunnval (15 
± 4 vs 16 ¢ 3 ram). 
Conclusion: Despite overall poor prognosis, long-term survival is possible 
=n treated pts with pnmary systemic amyloidosis and cardiac involvement 
including sunnval of -~10 years in 4% of pts. Higher inilial EF and longer 
mitral deceleration time were present in pts with tong-term survival. 
~ A  Comparative Echocardiographic Study of 
Primary, Familial and Secondary Amyloidosis 
I. Moyssakis. F. Triposkiadis, E. Chronakts, E. Kallieris, L. Rallidis, 
P. Nikoyannopoulos, M. Kyriakidis Department ot Cardiology, 
Hamreersmtth Hospital. London. UK: Department of Cardiology. Laiko 
Hospital, Athens. Greece 
Background: Amyloidosts (A) is characterized by the deposition of specific 
proteins in vanous organs. Currently recognized types include pnmary, sec- 
ondary and familial each of which may involve the heart. 
Material and Methcds: Lett ventncular (LV) morphology, LV diastolic and 
systolic function and right ventncular (RV) size and systolic function were 
echocardiographically (M-mode, 2D, pulsed and continuous Doppler) as- 
sessed in 28 patients with primary, 17 with familial and 11 with secondary 
A. To study disease progress in primary A, all patients underwent a repeat 
examination after a period of 15 ± 6 months. 
Results: Interventricular septal thickness (ram) was greater in primary 
or familial than in secondary A (14.1 ~_ 2.3 vs 13.9 ~- 1.98 vs 12.27 :~ 1 
respectively, p < 0.002) while LV posterior wall thickness (mm) was similar 
in the three groups (13.7 ± 2.4 vs 13.3 ~ 1.7 vs 12.18 ¢ 1.1. p = NS). LV 
fractional shortening (FS, %) was reduced in primary compared to familial 
(29,8 • 10.2 vs 36,2 ~: 65 vs p < 005. The fransmitlal flow velcc~'y (TFV) 
pattern was compatible with abnormal relaxatJ0n in most patients of the 3 
groul3s [primal: 16 (57%), familial: 1| (647%), secon~lry: 8 (72%), p = 
NS], RV thickening was preseht in 13 (46 4%) patients wdh primary. 6 (35%) 
with tt~mihat nd 1 (9%) w;th seconda~ A RV (fy~funclion was present in 
8 (28,6%), 2 (11.8%) and 0 patientS m=~pectn/ely. Rap#at exammat~0n Of
patients with primary A revealed detsherelion of LV systolic functc~n (FS 
236 ~ 8,8, p .~: 6.05 vs baseline) and increased froguency of LV reStrctK~ 
in TFV prolile (53.6% v~ 25% at baselino, p < 0.05). 
Conclusions: Primary amylotdosis causes more severe ¢~ia¢ involve. 
mont th~n the familial or secondary typQs, Progression of prima~ amytotdesis 
is rapid and t:haractarized by dets~nrelion el bolh left w~nt~ulaf (~asfol¢ 
and ~ystolic function. 
~ Echocltd iographl¢ Identlficatlon of CeRIia¢ 
AmyloldoSls I~tlents Capable of Undergoing 
Intenslv~ Treatment With Intravenous Melphelen 
Therapy 
LA  Mondes, JR, Reisinger, S.W. Dubrey, R Comenzo, E. Vosburgh, 
V. S~ncherawela, M. LaValloy, M. Skinner, R,H. Folk B~ston Medical 
Cent,,r. Boston. MA. USA 
Background: Pnmary amyloidests (AL) is a protein dopes;lion d;sease whch 
comes a poor prognosis, esl~'ciatly in patients (pts) with cardiac involvement, 
Intravenous melphalan (IViVt) toUowod by autologous tem cell transplanta. 
lion is an aggressive therapy which may produce disease remission and 
;reprove survwal. 
Methods and Res~jrts: To determine if pts with cardiac AL can be safely 
treated w~th this the, apy, we studied the echoca~lograms of 64 conse~utP/e 
pts undergoing IVM and measured seplal and POSterior wall (PW) thickness. 
LV end-diastolic diameter (LVEDD), LV mass, and tractional shortening (FS). 
Cardiac AL, defined as wall thickness > 1.1 cm, was present in 30 patients. 
After 6 months ot follow-up, 15 pts (50%) with cardiac amylord had died 
compa.'ed to 5 pts (15%) without cardiac disease (p = 0.006). Of me 30 pts 
with cardiac AL 9 died in the peri-therapy penod (~1 month) and 15 of the 
remaining 21 pts were alive at 6 months. 
Surwvat : n~nlh (n = 9) Surv'Nal :-1 month (n = 2 I) D value 
~eptum (cm) 1 43 ~ 022 1 30 • 0 13 0 07 
PW tom) 1 38~016 126 ~ ooa 001 
FS (%i 24 7 t- 8 S 3.3.6 +. 11 3 004 
There was no significant difference between the two groups wdh respect 
to LVEDD or LV mass. 
Conclusion: PTs w~th cardiac amylocd should not all be excluded from 
intensive IVM since careful echocardtographic evaluation peer to therapy 
can identify pts at high nsk for pen-treatment mortality. 
~ In(~idence of  Dilated Cardiomyopathy and 
Detection of  HIV in the Myoce~llal Cells In a Large 
Population of HIV.posltive Sub~::ts: A Long-term 
Clinical and Echocardiographlc FollOw-up 
G Barbaro, G. Di Lorenzo, B. Gnsorio t. G Barbarini "~. For the Gruppa 
Itah~ne per to Studio CaMiologlco dei pazienti affeffl da AIDS (G.I.S.CA]: 
Deparlment of Emergent, Medicine University "La Sapienza'. Rome, Italy: 
Division of Infectious Diseases, General Hospital. Foggia. Italy: 
Z Oepartment of Infectious Diseases, IRCCS Poticlinico S. MatteD. University 
of Pavia, Italy 
B~ckground: Human Immunodeticiency Virus (HIV) disease zs increasingly 
recognized as an important etiologic factor in Dilated Cardiomyopathy (DC). 
Aim of the study was to assess the incidence of echocarcliographically- 
diagnosed DC over time fn a large and selected population of HIV-positive 
subjects, correlabng the morphologic and functional parameters w~th clinical 
and virologic data. 
Method.?,: Nine hundred and fi~' two asymptomatic HIV*positive subject 
were long-term f011owod-up by clinical and echocardiographic examinations, 
which were pedormed, respectiveJy, every three and six months DC was 
defined as the presence of diffuse left ventncular hypokinesia (election frac- 
tion - 45%) and left ventncular dilatation (let ventdcular end--diastolic volume 
index >80 mVm2). The patients with echocardiographic diagnosis of DC un- 
derwent endomyocardial biopsy (EMB) for histolegic, immunohistol0gtc and 
virologic examination. 
Results: During the follow-up period (60 ± 5.3 months), echocardiographic 
diagnosis of DC was made in 76 patients (7.9%), with a mean incidence of 
1.2 new cases/month and 15.3 new cases/year. The relative risk for develop- 
ment of DC was greater i.n homosexuals patients, in those with a CD4+ cell 
count .:400/ram 3 and in those who received therapy with z~dovudine. All pa* 
tients with echocardiographie diagnosis of DC underwent EMB. Histological 
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